Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial
Whalen M, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Hoffmann T, Aweeka F, Parikh S, Mwebaza N. Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial. The Journal Of Clinical Pharmacology 2025 PMID: 39853752, DOI: 10.1002/jcph.6193.Peer-Reviewed Original ResearchDesbutyl-lumefantrineAntiretroviral therapyEfavirenz-based antiretroviral therapyEfavirenz-based HIV therapyEFV-based antiretroviral therapyEpisodes of malariaHIV co-infectionSignificant reductionExtended treatment durationStatistically significant reductionClinically significant reductionArtemether-lumefantrinePharmacodynamic trialsMalaria episodesPharmacokinetic samplingHIV therapyRandomized studyRecurrence riskDrug interactionsPrimary outcomeRegimensMalariaReinfection riskHIVCo-infection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply